PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats

Journal of Psychopharmacology

Volumn 25, Issue 2, 2011, Pages 263-273

  Higley, Amanda E ^a,b   Spiller, Krista ^a   Grundt, Peter ^a   Hauck Newman, Amy ^a   Kiefer, Stephen W ^b   Xi, Zheng Xiong ^a   Gardner, Eliot L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

brain reward; brain stimulation reward; cue induced reinstatement; D3 receptor; methamphetamine; PG01037; self administration

Indexed keywords

DOPAMINE 3 RECEPTOR BLOCKING AGENT; METHAMPHETAMINE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 2 YL)BENZAMIDE; PG 01037; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; BRAIN DEPTH STIMULATION; DRUG EFFECT; DRUG SEEKING BEHAVIOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD;

ANIMALS; BENZAMIDES; CONDITIONING, OPERANT; CUES; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; ELECTRIC STIMULATION; EXTINCTION, PSYCHOLOGICAL; MALE; METHAMPHETAMINE; PYRIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D3; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION; SUCROSE;

EID: 79551662129     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109358201     Document Type: Article

References (76)

1. Arnold JM, Roberts DC (1997) A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57: 441-457.
2. Ashby CR, Paul M., Gardner EL, Heidbreder CA, Hagan JJ (2003) Acute administration of the selective D3 receptors antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 48: 154-156.
3. Austin NE, Baldwin SJ, Cutler L., et al. (2001) Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011A in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 6: 677-686.
4. Bauco P., Wise RA (1997) Synergistic effects of cocaine with lateral hypothalamic brain stimulation reward: lack of tolerance or sensitization. J Pharmacol Exp Ther 283: 1160-1167.
5. Bossert JM, Ghitza UE, Lu L., Epstein DH, Shaham Y. (2005) Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526: 36-50.
6. Cervo L., Carnovali F., Stark JA, Mennini T. (2003) Cocaine-seeking behavior in response to drug-associated stimuli in rats: Involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology 28: 1150-1159.
7. Collins GT, Newman AH, Grundt P., et al. (2007) Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 193: 159-70 ).
8. Collins GT, Witkin JM, Newman AH, et al. (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314: 310-319.
9. Coulombe D., Miliaressis E. (1987) Fitting intracranial self-stimulation data with growth models. Behav Neurosci 101: 209-214.
10. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz JC, Sokoloff P. (2002) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. Journal of Neuroscience 20: 8677-8684.
11. Di Ciano P., Everitt BJ (2003) Differential control over drug-seeking behavior by drug-associated conditioned reinforcers and discriminative stimuli predictive of drug availability. Behav Neurosci 117: 952-960.
12. Di Ciano P., Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28: 329-338.
13. French ED, Lopez M., Peper S., Kamenka JM, Roberts DC (1995) A comparison of the reinforcing efficacy of PCP, the PCP derivatives TCP and BTCP, and cocaine using a progressive ratio schedule in the rat. Behav Pharmacol 6: 223-228.
14. Gal K., Gyertyán I. (2003) Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 14: 93-98.
15. Gardner EL (2000) What we have learned about addiction from animal models of drug self administration. Am J Addict 9: 285-313.
16. Gilbert JG, Newman AH, Gardner EL, et al. (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57: 17-28.
17. Gurevich EV, Joyce AN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20: 60-80.
18. Grundt P., Carlson EE, Cao J., et al. (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-butyl} arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48: 839-848.
19. Grundt P., Prevatt KM, Cao J., et al. (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: Potential substance abuse therapeutic agents. J Med Chem 50: 4135-4146.
20. Heidbreder CA, Gardner EL, Xi ZX, et al. (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49: 77-105.
21. Heidbreder CA, Andreoli M., Marcon C., Hutcheson DM, Gardner EL, Ashby CR, Jr. (2007) Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 12: 35-50.
22. Higley AH, Dillon C., Xi ZX, Gardner EL (2007) The dopamine D3 receptor antagonist SB-277011A inhibits progressive-ratio methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking behavior in rats. Abstracts for the 37th Annual Meeting for Society of Neuroscience ; 2007 November 3-7 San Diego, CA.
23. Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29: 565-598.
24. Jaffe JH, Cascell NG, Kumor KM, Sherer MA (1989) Cocaine-induced cocaine craving. Psychopharmacology 110: 76-84.
25. Kalivas PW (2007) Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 16: 71-8.
26. Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatr 162: 1403-1413.
27. Khroyan TV, Barrett-Larimore RL, Rowlett JK, Spealman D. (2000) Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 294: 680-687.
28. Kita K., Shiratani T., Takenouchi K., Fukuzako H., Takigawa M. (1999) Effects of D1 and D2 dopamine receptor antagonists on cocaine-induced self-stimulation and locomotor activity in rats. Eur Neuropsychopharmacol 9: 1-7.
29. Kornetsky C. (2004) Brain-stimulation reward, morphine-induced oral stereotypy, and sensitization: implications for abuse. Neurosci Biobehav Rev 27: 777-786.
30. Kumar R., Riddle L., Griffin SA, Grundt P., Newman AH, Luedtke RR (2009) Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56: 944-955.
31. Le Foll B., Sokoloff P., Stark H., Goldberg SR (2005) Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30: 720-730.
32. Levant B. (1998) Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 2: 269-274.
33. Mendelson JH, Mello NK (1996) Management of cocaine abuse and dependence. N Eng J Med 334: 965-972.
34. Meredith CW, Jaffe C., Ang-Lee K., Saxon AJ (2005) Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 13: 141-154.
35. National Academy of Sciences (National Research Council, Commission on Life Sciences, Institute of Laboratory Animal Resources) (1996) Guide for the Care and Use o Laboratory Animals. Washington, DC: National Academy Press.
36. Newman AH, Grundt P., Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48: 3663-3679.
37. OBrien CP (1997) A range of research-based pharmacotherapies for addiction. Science 278: 66-70.
38. OBrien CP, Childress AR, McLellan AT, Ehrman R. (1992) Classical conditioning in drug-dependent humans. Ann N Y Acad Sci 654: 400-415.
39. OBrien CP, Gardner EL (2005) Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 108: 18-58.
40. Pak AC, Ashby CR, Jr, Heidbreder CA, et al. (2006) The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9: 585-602.
41. Paxinos G., Watson C. (1998) The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press.
42. Peng XQ, Ashby CR Jr, Spiller K., Li X., Li J., Thomasson N., Millan MJ, Mocaër E., Mu?oz C., Gardner EL, Xi ZX (2009) The preferential dopamine D3 antagonist S33138 inhibits cocaine reward and cocaine triggered relapse to drug- seeking behavior in rats. Neuropharmacology, 56, 752-760.
43. Pierce RC, Kumaresan V. (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse ? Neurosci Biobehav Rev 30: 15-38.
44. Pilla M., Perachon S., Sautel F., et al. (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400: 371-375.
45. Ranaldi R., Beninger RJ (1994) The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Brain Res 651: 283-292.
46. Reavill C., Taylor SG, Wood MD, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294: 1154-1165.
47. Remington G., Kapur S. (2001) SB-277011 GlaxoSmithKline. Curr Opin Investig Drugs 2: 946-949.
48. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
49. Roberts DC, Loh EA, Vickers G. (1989) Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology 97: 535-538.
50. Rose ME, Grant CE (2008) Pharmacotherapy for methamphetamine dependence: A review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 20: 145-155.
51. Rowlett JK (2000) A labor-supply analysis of cocaine self-administration under progressive ratio schedules: antecedents, methodologies, and perspectives. Psychopharmacology 153: 1-16.
52. Schwartz A., Gozzi A., Reese T., et al. (2004) Selective dopamine D3receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 54: 1-10.
53. Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996) Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271: 1586-1589.
54. Shaham Y., Rodaros D., Stewart J. (1994) Reinstatement of heroin-reinforced behavior following long-term extinction: implications for the treatment of relapse to drug taking. Behav Pharmacol 5: 360-364.
55. Shalev U., Grimm JW, Shaham Y. (2002) Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54: 1-42.
56. Shalev U., Highfield D., Yap J., Shaham Y. (2000) Stress and relapse to drug seeking in rats: studies on the generality of the effect. Psychopharmacology (Berl) 150: 337-346.
57. Shalev U., Marinelli M., Baumann MH, Piazza PV, Shaham Y. (2003) The role of corticosterone in food deprivation-induced reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl) 168: 170-176.
58. Sinha R. (2001) How does stress increase risk of drug abuse and relapse ? Psychopharmacology 158: 343-359.
59. Spiller K., Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C., Gardner EL (2008). The putative dopamine D3 receptor antagonists SB-277011A, NGB 2904, S33,138 or BP 897 inhibit methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196: 533-542.
60. Sokoloff P., Diaz J., Le Foll B., et al. (2006) The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5: 25-43.
61. Sokoloff P., Giros B., Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
62. Sokoloff P., Le Foll B., Perachon S., Bordet R., Ridray S., Schwartz JC (2001) The dopamine D3 receptor and drug addiction. Neurotox Res 3: 433-441.
63. Sokoloff P., Martres MP, Giros B., Bouthenet ML, Schwartz JC (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43: 659-666.
64. Stafford D., LeSage MG, Glowa JR (1998) Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology 139: 169-184.
65. Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I., McGonigle P. (2000) Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and non-dopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295: 1223-1231.
66. Stein L., Ray OS (1960) Brain stimulation reward thresholds self-determined in rat. Psychopharmacologia 1: 251-256.
67. Stewart J. (2000) Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiat Neurosci 25: 125-136.
68. Thanos PK, Katana JM, Ashby CR, et al. (2005) The selective dopamine D3 antagonist SB-277011A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 81: 190-197.
69. Vorel SR, Ashby CR, Jr, Paul M., et al. (2002) Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22: 9595-9603.
70. Wise RA (1996 a) Addictive drugs and brain stimulation reward. Ann Rev Neurosci 19: 319-340.
71. Wise RA (2005) Forebrain substrates of reward and motivation. J Comp Neurol 493: 115-21.
72. Wise RA, Gardner EL (2004) Animal models of addiction. In: Charney DS, Nestler EJ (eds) Neurobiology of Mental Illness, 2 nd edn. London: Oxford University Press, 683-697.
73. Xi ZX, Gardner EL (2007) Pharmacological actions of NGB-2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 13: 1-21.
74. Xi ZX, Gilbert JG, Campos AC, et al. (2004) Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 176: 57-65.
75. Xi ZX, Gilbert JG, Pak AC, Ashby CR, Heidbreder CA, Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive ratio and variable cost variable payoff fixed ratio cocaine self administration in rats. Eur J Neurosci 21: 3427-3438.
76. Xi ZX, Newman AH, Gilbert JG, et al. (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaines rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31: 1393-1405.